![Karen Ferrante](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Karen Ferrante
Director/Board Member at
MACROGENICS, INC.
Net worth: 61 360 $ as of 2026-05-30
Profile
Karen Jean Ferrante is currently an Independent Director at Cogent Biosciences, Inc. since 2018, an Independent Director at MacroGenics, Inc. since 2017, and a Director at New England Women In Science Executives Club.
Former roles include Associate Director at Bristol Myers Squibb Co., Independent Director at Progenics Pharmaceuticals, Inc. from 2014 to 2020, Independent Non-Executive Director at HUTCHMED (China) Ltd. from 2017 to 2023, Independent Director at Baxalta, Inc. from 2015 to 2016, Vice President-Oncology Development at Pfizer Inc. from 1999 to 2007, Head-Oncology Therapeutic Area at Millennium Pharmaceuticals, Inc. in 2013, Chief Medical Officer at Takeda Pharmaceutical Co., Ltd. from 2007 to 2013, Chief Medical Officer and Head-Research & Technology at Tokai Pharmaceuticals, Inc. from 2014 to 2016, and Vice President-Oncology Department at Pfizer (St. Louis).
Education includes undergraduate studies at Providence College and a doctorate from Georgetown University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MACROGENICS, INC. 0.02% | 2026-05-18 | 14,750 ( 0.02% ) | 61 360 $ | 2026-05-30 |
| 2026-04-12 | 0 ( -.--% ) | - $ | 2026-05-30 |
Karen Ferrante active positions
| Companies | Position | Start |
|---|---|---|
| MACROGENICS, INC. | Director/Board Member | 2017-01-24 |
| COGENT BIOSCIENCES, INC. | Director/Board Member | 2018-01-31 |
New England Women In Science Executives Club
 New England Women In Science Executives Club Miscellaneous Commercial ServicesCommercial Services Operates as a women's club which allows members to discuss their challenges, solutions and ideas | Director/Board Member | - |
Former positions of Karen Ferrante
| Companies | Position | End |
|---|---|---|
| HUTCHMED (CHINA) LIMITED | Director/Board Member | 2023-05-11 |
| PROGENICS PHARMACEUTICALS, INC. | Director/Board Member | 2020-06-18 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel proprietary therapies for the treatment of prostate cancer and other hormonally driven diseases | Chief Tech/Sci/R&D Officer | 2016-08-30 |
| BAXALTA INC | Director/Board Member | 2016-06-02 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Chief Tech/Sci/R&D Officer | 2013-04-30 |
Training of Karen Ferrante
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
78
1st degree connections
14
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 14 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets medicines for prostate cancer | Health Technology |
HUTCHMED (China) Ltd.
 HUTCHMED (China) Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products | Health Technology |
Cogent Biosciences, Inc.
 Cogent Biosciences, Inc. BiotechnologyHealth Technology Discovers and develops new cellular immunotherapies for cancer | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. Pharmaceuticals: MajorHealth Technology Engages in research, development and manufacture of therapies and biopharmaceutical products | Health Technology |
Takeda Pharmaceutical Co., Ltd.
 Takeda Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the research, development, manufacturing and marketing of pharmaceutical products | Health Technology |
MacroGenics, Inc.
 MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Providence College
 Providence College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
 Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel proprietary therapies for the treatment of prostate cancer and other hormonally driven diseases | Health Technology |
Pfizer (St. Louis)
 Pfizer (St. Louis) BiotechnologyHealth Technology Provides research services in prescription medicines for humans and animals | Health Technology |
New England Women In Science Executives Club
New England Women In Science Executives Club Miscellaneous Commercial ServicesCommercial Services Operates as a women's club which allows members to discuss their challenges, solutions and ideas | Commercial Services |
- Stock Market
- Insiders
- Karen Ferrante
